These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37017026)

  • 21. Virologic Response to Dolutegravir Plus Lamivudine in People With Suppressed Human Immunodeficiency Virus Type 1 and Historical M184V/I: A Systematic Literature Review and Meta-analysis.
    Kabra M; Barber TJ; Allavena C; Marcelin AG; Di Giambenedetto S; Pasquau J; Gianotti N; Llibre JM; Rial-Crestelo D; De Miguel-Buckley R; Blick G; Turner M; Harrison C; Wynne T; Verdier G; Parry CM; Jones B; Okoli C; Donovan C; Priest J; Letang E
    Open Forum Infect Dis; 2023 Nov; 10(11):ofad526. PubMed ID: 38033982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of resistance mutations on efficacy of dolutegravir plus rilpivirine or plus lamivudine as maintenance regimens: a cohort study.
    Gagliardini R; Baccini M; Modica S; Montagnani F; Zanelli G; Borghetti A; Dreassi E; Lombardi F; Pecorari M; Borghi V; Callegaro A; Micheli V; Lodi MA; Rossetti B; Zazzi M;
    J Glob Antimicrob Resist; 2022 Mar; 28():274-281. PubMed ID: 35092828
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Durable Efficacy of Switching From a 3- or 4-Drug Tenofovir Alafenamide-Based Regimen to the 2-Drug Regimen Dolutegravir/Lamivudine in the TANGO Study Through Week 196.
    De Wit S; Bonnet F; Osiyemi O; Bisshop F; Olalla J; Routy JP; Wyen C; Moodley R; Pappa K; Wang R; Oyee J; Saggu P; Letang E; Wynne B; Jones B; Smith KY; Ait-Khaled M
    J Acquir Immune Defic Syndr; 2024 Mar; ():. PubMed ID: 38346427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. First case of Dolutegravir and Darunavir/r multi drug-resistant HIV-1 in Cameroon following exposure to Raltegravir: lessons and implications in the era of transition to Dolutegravir-based regimens.
    Fokam J; Takou D; Semengue ENJ; Teto G; Beloumou G; Dambaya B; Santoro MM; Mossiang L; Billong SC; Cham F; Sosso SM; Temgoua ES; Nanfack AJ; Moudourou S; Kamgaing N; Kamgaing R; Ngako Pamen JN; Etame MMN; Bissek AZ; Elat JN; Moussi EE; Colizzi V; Perno CF; Ndjolo A;
    Antimicrob Resist Infect Control; 2020 Aug; 9(1):143. PubMed ID: 32843050
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
    Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials.
    Cahn P; Madero JS; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man C; Currie A; Underwood M; Tenorio AR; Pappa K; Wynne B; Fettiplace A; Gartland M; Aboud M; Smith K;
    Lancet; 2019 Jan; 393(10167):143-155. PubMed ID: 30420123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Population Pharmacokinetic Model and Alternative Dosing Regimens for Dolutegravir Coadministered with Rifampicin.
    Kawuma AN; Wasmann RE; Dooley KE; Boffito M; Maartens G; Denti P
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0021522. PubMed ID: 35604212
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of three antiretroviral therapy regimens started in pregnancy up to 50 weeks post partum: a multicentre, open-label, randomised, controlled, phase 3 trial.
    Chinula L; Ziemba L; Brummel S; McCarthy K; Coletti A; Krotje C; Johnston B; Knowles K; Moyo S; Stranix-Chibanda L; Hoffman R; Sax PE; Stringer J; Chakhtoura N; Jean-Philippe P; Korutaro V; Cassim H; Fairlie L; Masheto G; Boyce C; Frenkel LM; Amico KR; Purdue L; Shapiro R; Mmbaga BT; Patel F; van Wyk J; Rooney JF; Currier JS; Lockman S;
    Lancet HIV; 2023 Jun; 10(6):e363-e374. PubMed ID: 37167996
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comedication prescription patterns and potential for drug-drug interactions with antiretroviral therapy in people living with human immunodeficiency virus type 1 infection in Germany.
    Lopes S; O'Day K; Meyer K; Van Stiphout J; Punekar Y; Radford M; Haas JS
    Pharmacoepidemiol Drug Saf; 2020 Mar; 29(3):270-278. PubMed ID: 31950545
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
    Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
    HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A Comprehensive Literature Review of Treatment-Emergent Integrase Resistance with Dolutegravir-Based Regimens in Real-World Settings.
    Henegar C; Letang E; Wang R; Hicks C; Fox D; Jones B; de Ruiter A; Vannappagari V
    Viruses; 2023 Dec; 15(12):. PubMed ID: 38140667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
    Romo ML; Brazier E; Mahambou-Nsondé D; De Waal R; Sekaggya-Wiltshire C; Chimbetete C; Muyindike WR; Murenzi G; Kunzekwenyika C; Tiendrebeogo T; Muhairwe JA; Lelo P; Dzudie A; Twizere C; Rafael I; Ezechi OC; Diero L; Yotebieng M; Fenner L; Wools-Kaloustian KK; Shah NS; Nash D;
    J Int AIDS Soc; 2022 Jul; 25(7):e25961. PubMed ID: 35848120
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dolutegravir for first-line antiretroviral therapy in low-income and middle-income countries: uncertainties and opportunities for implementation and research.
    Dorward J; Lessells R; Drain PK; Naidoo K; de Oliveira T; Pillay Y; Abdool Karim SS; Garrett N
    Lancet HIV; 2018 Jul; 5(7):e400-e404. PubMed ID: 29884404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic review of the genetic mechanisms of dolutegravir resistance.
    Rhee SY; Grant PM; Tzou PL; Barrow G; Harrigan PR; Ioannidis JPA; Shafer RW
    J Antimicrob Chemother; 2019 Nov; 74(11):3135-3149. PubMed ID: 31280314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment Switch to Dolutegravir With 2 Nucleoside Reverse-Transcriptase Inhibitors (NRTI) in Comparison to Continuation With Protease Inhibitor/Ritonavir Among Patients With Human Immunodeficiency Virus at Risk for Prior NRTI Resistance: A Cohort Analysis of Real-World Data.
    Sangaré MN; Baril JG; de Pokomandy A; Ferreira Guerra S; Carabali M; Laprise C; Thomas R; Klein M; Tremblay C; Roger M; Pexos C; Greenwald ZR; Machouf N; Durand M; Hardy I; Dakouo M; Trevisan A; Laporte L; Schnitzer ME; Trottier H
    Open Forum Infect Dis; 2020 Nov; 7(11):ofaa404. PubMed ID: 33204746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dolutegravir in HIV-2-Infected Patients With Resistant Virus to First-line Integrase Inhibitors From the French Named Patient Program.
    Descamps D; Peytavin G; Visseaux B; Tubiana R; Damond F; Campa P; Charpentier C; Khuong-Josses MA; Duvivier C; Karmochkine M; Lukiana T; Matheron S
    Clin Infect Dis; 2015 May; 60(10):1521-7. PubMed ID: 25690598
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study.
    van Wyk J; Ait-Khaled M; Santos J; Scholten S; Wohlfeiler M; Ajana F; Jones B; Nascimento MC; Tenorio AR; Smith DE; Wright J; Wynne B
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):794-800. PubMed ID: 33587500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence and Patterns of Adverse Drug Events Among Adult Patients with Human Immune Virus Infection on Dolutegravir-Based Antiretroviral Drug Regimens in Amhara Comprehensive Specialized Hospitals, Northwest Ethiopia: A Multicenter Retrospective Follow-Up Study.
    Zemariam AB; Tadesse YB; Kassaw AT
    HIV AIDS (Auckl); 2023; 15():271-278. PubMed ID: 37283816
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children.
    Singh RP; Adkison KK; Baker M; Parasrampuria R; Wolstenholme A; Davies M; Sewell N; Brothers C; Buchanan AM
    Pediatr Infect Dis J; 2022 Mar; 41(3):230-237. PubMed ID: 34817414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro assessment of the potential for dolutegravir to affect hepatic clearance of levonorgestrel.
    Roberts O; Kinvig H; Owen A; Lamorde M; Siccardi M; Scarsi KK
    HIV Med; 2021 Nov; 22(10):898-906. PubMed ID: 34328253
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.